TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female \> 1 year~* diagnosed of Fanconi's anemia confirmed by instability chromosomal test with diepoxy-butane or mitomycin C~* At least one of the following parameters must be higher than these values: Hemoglobin:8,0 g/dL; neutrophils: 750/mm3; platelets: 30.000/mm3~* Lansky index\> 60%.~* Left ventricular ejection fraction \>50%.~* To grant informed consent in agreement with current law norms~* Women in childbearing age must obtain a negative result in the pregnancy test in serum or urine in the visit of selection and accept the use of suitable contraceptive methods since at least 14 days prior to the first dose of mobilizing treatment until the 14 days following the last~Exclusion Criteria:~* Evidence of myelodysplastic syndromes or leukemia, or cytogenetic abnormalities predicted of these syndromes in bone marrow aspiration. Cytogenetic analyses performed 2 months before starting study are accepted~* Patients with active infection process or any other underlaying severe medical process~* Severe Functional alteration of organs (hepatic, renal, respiratory)(?3), according to National Cancer Institute (NCI CTCAE v3) criteria~* Haematopoietic transplant~* Any disease or concomitant process that is not compatible with the study as per investigator opinion~* Patients not elegible because of an psico-social evaluation~* Patients that received transfusional support during the last 3 months.~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- plerixafor and filgrastim treatment (Type: EXPERIMENTAL): to assess the safety and efficacy of CD34+ cells mobilization with plerixafor and filgrastim

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All children up to 21 years of age, with central catheters (any type) that develop symptoms and are admitted to CHM with an underlying H/O/BMT diagnosis for individual episodes of suspected or proven CRI of the blood, including rule out sepsis, will be screened for potential participation in this study.~* Individual CRI episodes in the same patient will be defined as a distinct central catheter associated blood stream infection if separated by greater than 28 days from prior ELT procedure and caused by a different organism identified on culture than the prior central catheter associated blood stream infection episode.~* Participants meeting study enrollment criteria will be offered participation and must have parental full informed consent, adolescent assent and young child verbal assent prior to enrollment as applicable.~Exclusion Criteria:~* Children with documented allergy to ethanol or alcohol will be excluded. Blood cultures from patients that are reported positive for pathogen growth within 12 hours from the time they are obtained will be excluded from the study.~* Any patient at CHM with an infected central catheter and with another indwelling foreign body that communicates directly with the bloodstream, of which infection or colonization could not be excluded directly, will also be excluded from the study (i.e. Left Ventricular Assist Device) as it will not be possible to assess sterilization of the central catheter.~* Any patient with endocarditis or presumed endovascular infection will also be excluded.~* Any patient deemed critically ill or unstable, upon admission or during the early treatment course, in which case the treating clinician(s) feel that immediate line removal is potentially life-saving will be excluded from the study.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Pre-emptive Ethanol Lock Therapy Group (Type: EXPERIMENTAL): Participants receive ethanol lock before blood cultures grow germ
- Standard Ethanol Lock Therapy Group (Type: ACTIVE_COMPARATOR): Participants receive ethanol lock if and only after blood cultures grow germ

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects at least 18 years of age with center-involved macular edema secondary to CRVO with mean central retinal thickness ≥ 250 μm on OCT~* ETDRS best corrected visual acuity of 20/40 to 20/320 (73 to 24 letters) in the study eye~Exclusion Criteria:~* Previous treatment with anti-angiogenic drugs in the study eye (Pegaptanib sodium,anecortave acetate, bevacizumab, ranibizumab, etc.)~* Prior panretinal laser photocoagulation or macular laser photocoagulation in the study eye~* CRVO disease duration \> 9 months from date of diagnosis~* Previous use of intraocular corticosteroids in the study eye or use of periocular corticosteroids in the study eye within the 3 months prior to Day 1~* Iris neovascularization, vitreous hemorrhage, traction retinal detachment, or preretinal fibrosis involving the macula in either the study eye or fellow eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VEGF Trap-Eye (Type: EXPERIMENTAL): Monthly IVT injection of VEGF Trap-Eye 2.0 mg until Week 24 Primary Endpoint
- Sham (Type: SHAM_COMPARATOR): Monthly Sham IVT injection until Week 24 Primary Endpoint

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alternative Antibiotic Regime in the Treatment of GAgP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The periodontal diagnosis of subjects with GAgP was established on the basis of clinical and radiographic criteria defined by the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions.~* Patients were included if they were between 18 and 35 years of age and otherwise healthy.~Exclusion Criteria:~* if the patients had any known systemic diseases or conditions that can/could influence the periodontal status (cancer, cardiovascular and respiratory diseases)~* history of hepatitis or HIV infection,~* immunosuppressive chemotherapy~* current pregnancy, planning a pregnancy or lactation~* requirement for antibiotic prophylaxis~* oral diseases other than GAgP, ongoing orthodontic therapy~* a history of antibiotic therapy or periodontal treatment within the preceding six months.~* Subjects were excluded if they had known allergies to quinolones or penicillin or metronidazole~* Not willing to participate to the study.~* Not accept to sign written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- amoxicillin+metronidazole (Type: ACTIVE_COMPARATOR): amoxicillin+metronidazole group received a combination of 500 mg of amoxicillin and 500 mg metronidazole three times per day for 7 days.
- moxifloxacin (Type: EXPERIMENTAL): The moxifloxacin group received 400 mg moxifloxacin, once in a day for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥ 3 months and \< 21 years~* Patients diagnosed with malignant hemopathies (Acute Lymphoblastic leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma (NHL)) in complete morphological remission or Myelodysplastic Syndromes (MDS), Solid Tumors or non malignant hematological disorders (SCID, Acquired and Congenital Aplastic Anemia, other Primary Immunodeficiencies, Life-threatening Cytopenia) eligible for an allogeneic transplantation and lacking a related or unrelated HLA-matched donor~* Patients displaying an HLA-partially matched family donor~* Lansky/Karnofsky score \> 40, WHO \> 4~* Signed written informed consent~Exclusion Criteria:~* Grade \>II acute GvHD or chronic extensive GvHD at the time of inclusion~* Patient receiving an immunosuppressive treatment for GvHD treatment at the time of inclusion~* Dysfunction of liver (ALT/AST \> 5 times normal value, or bilirubin \> 3 times normal value), or of renal function (creatinine clearance \< 30 ml / min)~* Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction \<40%)~* Current active infectious disease (including positive HIV serology or viral RNA)~* Serious concurrent uncontrolled medical disorder~* Pregnant or breast feeding female patient~* Lack of parents' informed consent.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- TCR alfa beta depleted graft, infusion (Type: EXPERIMENTAL): The leukapheresis product will undergo TCR alfa beta negative selection following the standardized protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Durability of Nevirapine-Based Antiretroviral Regimen

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected individuals ≥15 years of age~* CD4 cell count \<350 cells/mm3~* Willing to participate and give consent form~Exclusion Criteria:~* previous antiretroviral therapy~* pregnancy~* receiving a medication that has drug-drug interactions with NVP or RFP~* aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \>5 times of upper limit of normal range

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* The participant has confirmed acid alpha-glucosidase (GAA) enzyme deficiency from any tissue source and/or 2 confirmed GAA gene mutations.~* The participant must provide signed, informed consent prior to performing any study related procedures. Consent of a legally authorized guardian(s) is (are) required for legally minor participant as defined by local regulation. If the participant is legally minor, signed written consent shall be obtained from parent(s)/legal guardian and assent obtained from participants, if applicable.~Exclusion criteria:~* The participant is \<3 years of age.~* The participant has known Pompe specific cardiac hypertrophy.~* The participant is wheelchair dependent.~* The participant is not able to ambulate 40 meters (approximately 130 feet) without stopping and without an assistive device.~* The participant requires invasive-ventilation (non-invasive ventilation is allowed).~* The participant is not able to successfully perform repeated forced vital capacity (FVC) measurements in upright position of greater than or equal to 30% predicted and less than or equal to 85% predicted.~* The participant (and participant's legal guardian if participant is legally minor as defined by local regulation) is (are) not able to comply with the clinical protocol.~* The participant has had previous treatment with alglucosidase alfa or any investigational therapy for Pompe disease.~* The participant has prior or current use of immune tolerance induction therapy.~* The participant, if female and of childbearing potential, has a positive pregnancy test (beta-human chorionic gonadotropin) at baseline.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- avalglucosidase alfa (GZ402666) (Type: EXPERIMENTAL): Administered intravenously every 2 weeks
- alglucosidase alfa (GZ419829) (Type: ACTIVE_COMPARATOR): Administered intravenously every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA - SCREENING:~Age 14 to 65.~Both genders.~Not pregnant or breastfeeding by history.~EXCLUSION CRITERIA - SCREENING:~Non-volunteers.~Age less than 14 or greater than 65.~Pregnant or breastfeeding by history.~INCLUSION CRITERIA - TREATMENT:~Age 14 to 65 years.~Men and non-pregnant or breastfeeding women.~EXCLUSION CRITERIA - TREATMENT:~Non-volunteers.~Age less than 14 or greater than 65.~Pregnancy or breast-feeding.~Hgb less than or equal to 10 g/dl.~Cr greater than 1.4/100 ml.~ALT greater than 45 U or bilirubin greater than 1.5.~Weight less than 40 kg.~Heavy alcohol use (more than 1 beer or other alcohol-containing drink/day).~Temperature greater than 37.5C or other serious medical illnesses.~History of allergy to doxycycline or other tetracyclines.~History of HIV infection or other immunocompromised state.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: When to Start Anti-HIV Drugs in Patients With Opportunistic Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Note: Participants who enrolled in this study prior to Version 3.0 will be offered and allowed to switch to FTC/TDF if they wish. However, participants under the age of 18 cannot receive FTC/TDF through this study.~Inclusion Criteria for Step 1:~* HIV-1 infected~* Currently being treated for OI (including Pneumocystis carinii pneumonia \[PCP\]; cryptococcal meningitis; disseminated histoplasmosis; disseminated Mycobacterium avium complex \[MAC\]; cytomegalovirus \[CMV\] retinitis; CMV encephalitis; toxoplasmic encephalitis; other atypical non-tuberculous, non-MAC mycobacterial infections; or other serious, invasive BIs). Participants who have tuberculosis (TB) alone are ineligible for this study. Participants with bacterial pneumonia or serious BI must have a CD4 count less than 200 cells/mm3 within 30 days prior to study entry. Participants with other serious OIs, including other AIDS-defining and -related OIs for which appropriate therapy other than ART exists are eligible, pending investigator approval. Participants' current OI treatment must have been started within 14 days prior to study entry, but may have been discontinued prior to study entry.~* Able to take oral medications~* Parent or guardian willing to provide informed consent, if applicable~* Willing to use acceptable methods of contraception~Exclusion Criteria for Step 1:~* Any ART within 8 weeks prior to study entry~* 31 or more days of any ARV within 6 months prior to entry~* History of more than one virologic, immunologic, or clinical treatment failure while on a HAART regimen, or a history of more than one regimen change for unknown reasons~* Systemic cancer chemotherapy within 30 days prior to study entry~* Immunomodulators within 30 days prior to study entry, including growth factors, immune globulin, interleukins, and interferons (unless for hepatitis C virus or Kaposi's sarcoma)~* Investigational ARV agents at study entry~* Systemic investigational agents (except ARV drugs) within 30 days prior to study entry will be allowed at the study official's discretion~* Anticipated use of certain medications~* Kidney failure requiring dialysis~* Current drug or alcohol use that, in the opinion of the study official, would interfere with the study~* Treatment for current, first-treated, and diagnosed OI or BI for more than 14 days prior to study entry~* Known resistance to ART that prohibits administration of an effective ART regimen~* Current OI has recurred within 90 days prior to study entry. Recurrent BIs are not excluded.~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female (of nonchildbearing potential, practicing total abstinence, sexually active with female partners only, or using allowed contraceptive methods) at least 18 years of age at time of screening.~* Screening laboratory result indicating HCV GT3 infection.~* Chronic HCV infection, defined as one of the following:~  * Positive for anti-HCV antibody (Ab) or HCV RNA at least 6 months before screening; or~ * A liver biopsy consistent with chronic HCV infection; or~ * Abnormal alanine aminotransferase (ALT) levels for at least 6 months before screening.~* Hepatitis C virus treatment-naïve (i.e., participant had never received any anti-HCV treatment).~* Documented as noncirrhotic.~Exclusion Criteria:~* Female who was pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner was pregnant or planning to become pregnant during the study.~* Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could have precluded adherence to the protocol in the opinion of the investigator.~* Positive test result at screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus Ab (HIV Ab).~* Hepatitis C virus genotyping performed during screening indicated co-infection with more than one HCV genotype.~* Any cause of liver disease other than chronic HCV infection.~* Consideration by the investigator, for any reason, that the participant was an unsuitable candidate to receive ABT-493/ABT-530, SOF, or DCV.~* History of severe, life-threatening, or other significant sensitivity to any excipients of the study drug.~* Previous use of any anti-HCV treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
- Arm B (Type: ACTIVE_COMPARATOR): Sofosbuvir 400 mg once daily (QD) co-administered with daclatasvir 60 mg QD for 12 weeks.
- Arm C (Type: EXPERIMENTAL): ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Improve Care Coordination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~VA Patient~* Receives health care from VA and non-VA provider~* Diagnosed with a chronic health condition~* Prescribed 5 or more medications~* Upcoming VA and non-VA appointments within the study time frame~* Registered or willing to become registered with My HealtheVet~* Access to a computer with internet, phone, and a printer.~* English speaking~VA or Non-VA Providers: provide care to a stuy participant~Exclusion Criteria:~* Previously shared health data with a provider via their My HealtheVet or local provider patient portal~* No scheduled VA or non-VA appointments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: NO_INTERVENTION): Veterans randomized to usual care will not receive any training on using their patient portal(s) to access and share information. They will be contacted via phone and/or secure messaging to remind him/her to take the VA or non-VA provider packet to their appointment. At the conclusion of the study, Veterans assigned to usual care will be provided the training information on the VA health summary for their own reference.
- Care Coordination (Type: ACTIVE_COMPARATOR): Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete